True North Therapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 17
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $825M
Latest Deal Amount

True North Therapeutics General Information

Description

Developer of innovative antibody therapeutics targeting the classical pathway of the complement system. The company's monoclonal antibody to treat cold agglutinin disease TNT009, selectively targets the classical pathway of the complement system and prevents the generation of critical inflammatory mediators and phagocytic markers not addressed by other therapeutic approaches that act by inhibiting the complement system further downstream.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 951 Gateway Boulevard
  • South San Francisco, CA 94080
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

True North Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 28-Jun-2017 $825M 00000 00000 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series D) 18-Oct-2016 0000 00000 00000 Completed Clinical Trials - Phase 1
5. Secondary Transaction - Private 0000 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series C) 03-Dec-2015 0000 0000 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 07-Apr-2015 0000 0000 00000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 17-Jun-2014 $22M $22M 0000 Completed Startup
1. Accelerator/Incubator Completed Startup
To view True North Therapeutics’s complete valuation and funding history, request access »

True North Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00.0 00.0 00.0 00 00.0 00.000
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 29,166,580 $0.000100 $0.1 $1.2 $1.2 1x $1.2 21.6%
Series A 23,856,206 $0.000100 $0.08 $1 $1 1x $1 17.67%
To view True North Therapeutics’s complete cap table history, request access »

True North Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of innovative antibody therapeutics targeting the classical pathway of the complement system. The company's mo
Drug Discovery
South San Francisco, CA
17 As of 2016
00000
0000 0000-00-00
000000&0 00000

00000000

amco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volu
0000000000000
Tucson, AZ
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

00000000

idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l
0000000000000
Bedford, MA
000 As of 0000
00000
0000 0000-00-00
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

True North Therapeutics Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Calimmune Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
00000000 000000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
00000000 Formerly VC-backed Paris, France 00 000.00 000000000 000.00
00000 000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
You’re viewing 5 of 41 competitors. Get the full list »

True North Therapeutics Executive Team (12)

Name Title Board Seat Contact Info
Nancy Stagliano Ph.D Co-Founder, Chief Executive Officer & Board Member
Adam Rosenthal Ph.D Chief Business Officer
Graham Parry Ph.D Vice President, Technical Operations
You’re viewing 3 of 12 executive team members. Get the full list »

True North Therapeutics Board Members (8)

Name Representing Role Since
Nancy Stagliano Ph.D True North Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 1 of 8 board members. Get the full list »

True North Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

True North Therapeutics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ATEL Capital Group Growth/Expansion Minority 000 0000 000000 0
Baxalta Corporation Minority 000 0000 000000 0
Baxter Ventures Corporate Venture Capital Minority 000 0000 000000 0
Biogen Corporation Minority 000 0000 000000 0
California Institute for Quantitative Biosciences Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »